Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of Oral ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE)

NCT07440537 is registered in ClinicalTrials.gov with Beijing InnoCare Pharma Tech Co., Ltd. as lead sponsor.

NCT NCT07440537
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07440537 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of Oral ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE)
Lead sponsor
Beijing InnoCare Pharma Tech Co., Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
April 27, 2026
Completion date
December 31, 2027
Enrollment
105 (estimated)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous lupus erythematosus (cle)